Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. - Wikidata - awgldk - TriplyDB

Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study.

Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study.

http://www.wikidata.org/entity/Q34272038

about

Update in lung cancer and mesothelioma 2012 Immune checkpoint inhibitors: the new frontier in non-small-cell lung cancer treatment Radiotherapy combination opportunities leveraging immunity for the next oncology practice The European Organization for Research and Treatment of Cancer perspective on designing clinical trials with immune therapeutics Mechanisms of immune evasion and current status of checkpoint inhibitors in non-small cell lung cancer Non-small cell lung cancer: current treatment and future advances Checkpoint Inhibitors and Their Application in Breast Cancer Profile of nivolumab in the treatment of metastatic squamous non-small-cell lung cancer Immunotherapy for lung cancer: advances and prospects Immunotherapy for lung cancer Cancer immunotherapy: the beginning of the end of cancer?Cancer stem cells and immunoresistance: clinical implications and solutions New strategies in immunotherapy for non-small cell lung cancer Novel radiotherapy approaches for lung cancer: combining radiation therapy with targeted and immunotherapies Novel therapies in small cell lung cancer Treatment of advanced squamous cell carcinoma of the lung: a review Overview of current immunotherapeutic strategies for glioma Advances in immunotherapy for treatment of lung cancer Fueling the engine and releasing the break: combinational therapy of cancer vaccines and immune checkpoint inhibitors Exploiting the Immunomodulatory Properties of Chemotherapeutic Drugs to Improve the Success of Cancer Immunotherapy Current Status and Development of Traditional Chemotherapy in Non-small Cell Lung Cancer under the Background of Targeted Therapy Differences in driver genes between smoking-related and non-smoking-related lung cancer in the Chinese population The Evolution of Therapies in Non-Small Cell Lung Cancer Immune Checkpoint Blockade: A New Paradigm in Treating Advanced Cancer Immune Effects of Chemotherapy, Radiation, and Targeted Therapy and Opportunities for Combination With Immunotherapy The Efficacy of Combining EGFR Monoclonal Antibody With Chemotherapy for Patients With Advanced Nonsmall Cell Lung Cancer: A Meta-Analysis From 9 Randomized Controlled Trials The past, present and future of immunotherapy against tumor The latest therapeutic strategies after resistance to first generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) in patients with non-small cell lung cancer (NSCLC)New modalities of cancer treatment for NSCLC: focus on immunotherapy Immune Checkpoint Blockade in Cancer Therapy Systemic and targeted therapies for early-stage lung cancer Progress in immunotherapy for non-small cell lung cancer Immunotherapy advances for glioblastoma Combining radiation and immunotherapy: a new systemic therapy for solid tumors?Immunotherapy in the treatment of non-small cell lung cancer 50 Years of progress in the systemic therapy of non-small cell lung cancer The Evolving Role of Immune Checkpoint Inhibitors in Cancer Treatment Targeted therapies in development for non-small cell lung cancer Combination Approaches with Immune-Checkpoint Blockade in Cancer Therapy The Utilization of the Immune System in Lung Cancer Treatment: Beyond Chemotherapy

P2860

Q24619675-1D9FCB4C-275F-42E2-BF5B-1BED8F9C57D1 Q26738359-018EDFB6-F03B-4C1C-BDE1-F9A2620E7D8F Q26738443-87197457-8EF4-4F55-9CF3-5FAA539FAAAF Q26738677-73797248-C762-4ECB-BA72-34B2235EECBE Q26740288-93C9268D-4756-4A0E-A276-ECC15D2CFC63 Q26740333-D284FB2C-D984-48DD-A96E-4CD3ED5DE296 Q26745442-7DD6E679-D70B-4240-8D8F-65EB5551BBD3 Q26745590-D6EB4027-C821-4826-8270-6E4D5176A402 Q26750617-22B005AD-4482-43E9-9EAE-72DD31AD4334 Q26751254-C069DF44-FD32-42E8-B309-227E4879F3B5 Q26752277-5CCCA091-EFF4-499A-A7B7-EB943875900A Q26769757-E03FB0EA-A453-41C9-9657-5C2460A14148 Q26775385-D714E8C1-0C19-48CA-99E9-8148DD7D1F6E Q26775388-31F314C8-ADF5-48F2-9A53-0BA67FA6081E Q26775390-9E0FE2A3-11C1-46ED-AC63-B8A8A1611EEE Q26775392-8B96A7C0-C30D-47AD-9947-72D07354224D Q26776345-1163B6CB-702C-4A7D-9279-A932FDEBCD0E Q26778790-D24BB001-A7BF-4C4A-849C-C8D9A67AC6C0 Q26778793-BE40ABEB-CCAA-438A-A33B-A53699E5B482 Q26779184-CBD2D507-A2B7-4041-B0C0-02B0BDC5E9AC Q26783432-AF742D52-28A3-4C76-A2C8-B97A1313797F Q26786594-DCC60E50-7744-49FB-9B1E-0441A723DFD3 Q26786932-01C3535C-9D2B-4B95-9573-0EDC2280F22A Q26795509-EFB5184B-542C-4CD3-9F67-EB20FB504910 Q26796309-EF0B2DD5-BFA9-4697-951A-BA55C57013ED Q26796549-37A5239F-DAB4-4017-9BF2-8B672135E76D Q26799896-27F09A28-D88F-46CF-BE10-9C900EBEC4CC Q26823305-F270569F-F39E-43E1-B1C9-B3DBBE6A440E Q26829161-E1147E08-EED9-41C2-9E32-A0C9E4A1F515 Q26830509-2394EA65-C11A-4895-A4D4-13411553E90C Q26865490-0590CF6E-C4F2-4C9B-A8A5-D1D83B36788E Q26865725-B11B1E18-BF13-41A2-BA84-7409AA8A6FE8 Q26866513-A89FBBFB-7D01-4A8D-A9B9-248235CEBA37 Q26991721-04431F3C-9DD9-4E2A-9FFE-E4A23F713231 Q27000382-DE9D6428-43B8-421F-9DC9-8E75FE14FF95 Q27014978-58BB0156-C428-47C0-8956-0AF7CD46D1E6 Q27022789-A2984EA4-D7DB-4712-9842-5A553B5D88F8 Q27022852-47E70B43-F857-48FB-8934-29B8A56CFD59 Q28066199-F8504A1D-A338-403C-92A5-7CEE71ABE6B1 Q28066568-B4FA703D-9DF5-4BCC-8DB3-A2E9AD3C175E

P2860

Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study.

http://www.wikidata.org/entity/Q34272038

description

2012 nî lūn-bûn

@nan

2012 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Ipilimumab in combination with ...... d, multicenter phase II study.

@ast

Ipilimumab in combination with ...... d, multicenter phase II study.

@en

Ipilimumab in combination with ...... d, multicenter phase II study.

@nl

type

label

Ipilimumab in combination with ...... d, multicenter phase II study.

@ast

Ipilimumab in combination with ...... d, multicenter phase II study.

@en

Ipilimumab in combination with ...... d, multicenter phase II study.

@nl

prefLabel

Ipilimumab in combination with ...... d, multicenter phase II study.

@ast

Ipilimumab in combination with ...... d, multicenter phase II study.

@en

Ipilimumab in combination with ...... d, multicenter phase II study.

@nl

P1433

Q34272038-56936DF3-9681-4C9D-A264-ADB30620D249

P1476

Q34272038-F09DD6CF-5BE8-4FF2-AE8C-8FA9B41EE10D

P2093

Q34272038-000C9BFC-1BC5-4F4C-B0B7-9E8BE7817584

Q34272038-0CFDA00C-BBB4-4DD9-8CB8-A88EF0881DC3

Q34272038-4BDEA42A-94D4-4A45-8166-5DC8A6EA5718

Q34272038-5EECCBAC-9BDC-4653-8B72-553DF9FC449E

Q34272038-6F0126A4-68A2-458E-948D-E8F2BCE6D414

Q34272038-8293F595-8220-4595-B043-3664BB036C13

Q34272038-91628094-D8D9-46EA-88BA-8CDE9C3AF998

Q34272038-B931C728-57A7-4065-B55E-3AB5E3AFFF07

Q34272038-C927F5B2-EC7B-4710-811E-850C69376504

Q34272038-E33FDCAE-98ED-4C63-A6FD-C0959998EA95

P304

Q34272038-6C701CF8-7B63-4E23-83B1-7EFE95E196B9

P31

Q34272038-E1BE167B-CBB0-42B1-A927-9FAD279C9F20

P356

Q34272038-5C7BA186-FBEB-4A7F-A1CF-548BB5E8E033

P407

Q34272038-BF8359CD-AB4C-4380-877E-C785DDB34F83

P433

Q34272038-5043AAA1-664D-4BFA-913E-BC496DFF644F

P478

Q34272038-BE548833-4449-4788-A680-A93773D3E9C1

P50

Q34272038-70576442-9F01-4B6D-8873-E353C16D9819

P577

Q34272038-18E80C61-2C94-4BCC-9F15-343080AC43A0

P698

Q34272038-AC918FDC-CB4E-4061-AC6A-BCA3C0185CE5

P921

Q34272038-924CD0B9-C4EE-4584-A3AB-61F01D6A2E4B

Q34272038-A7D4398D-9424-413A-B601-3EBB3708552B

P356

JCO.2011.38.4032

P1433

Journal of Clinical Oncology

P1476

Ipilimumab in combination with ...... nd, multicenter phase II study

@en

P2093

Alexander Luft

http://www.w3.org/2001/XMLSchema#string

Fabrice Barlesi

http://www.w3.org/2001/XMLSchema#string

Haolan Lu

http://www.w3.org/2001/XMLSchema#string

Jean-Marie Cuillerot

http://www.w3.org/2001/XMLSchema#string

Joel Neal

http://www.w3.org/2001/XMLSchema#string

Martin Reck

http://www.w3.org/2001/XMLSchema#string

Martin Sebastian

http://www.w3.org/2001/XMLSchema#string

Piotr Serwatowski

http://www.w3.org/2001/XMLSchema#string

Raju Chacko

http://www.w3.org/2001/XMLSchema#string

Thomas J Lynch

http://www.w3.org/2001/XMLSchema#string

P304

2046-2054

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2011.38.4032

http://www.w3.org/2001/XMLSchema#string

P407

P433

17

http://www.w3.org/2001/XMLSchema#string

P478

30

http://www.w3.org/2001/XMLSchema#string

P50

Igor N. Bondarenko

P577

2012-04-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22547592

http://www.w3.org/2001/XMLSchema#string

P921

multicenter trial